# Dapagliflozin Effects on Epicardial Fat

Study · id `cardio:ct-nct02235298` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02235298](<https://clinicaltrials.gov/study/NCT02235298>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02235298

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02235298. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2020-09-10 (actual). Results posted on 2021-02-16.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Started: 2015-09 (actual) (ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Primary completion: 2020-09-10 (actual) (ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Completion: 2020-09-10 (actual) (ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Results first posted: 2021-02-16 (ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02235298, source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02235298-2021-02-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin Effects on Epicardial Fat
- Condition: Type 2 Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: University of Miami
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: b6944fa29bfae33febf9064c39ed66351022e64dcac10912bb5e5f7c508a9b70
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
